vs
Axsome Therapeutics, Inc.（AXSM）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Axsome Therapeutics, Inc.的季度营收约是STURM RUGER & CO INC的1.3倍（$196.0M vs $151.1M），Axsome Therapeutics, Inc.同比增速更快（65.0% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-18.7M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs 5.1%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
AXSM vs RGR — 直观对比
营收规模更大
AXSM
是对方的1.3倍
$151.1M
营收增速更快
AXSM
高出61.4%
3.6%
自由现金流更多
RGR
多$31.1M
$-18.7M
两年增速更快
AXSM
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.0M | $151.1M |
| 净利润 | $-28.6M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | -13.8% | 2.3% |
| 净利率 | -14.6% | — |
| 营收同比 | 65.0% | 3.6% |
| 净利润同比 | 61.9% | — |
| 每股收益（稀释后） | $-0.55 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMRGR
| Q4 25 | $196.0M | $151.1M | ||
| Q3 25 | $171.0M | $126.8M | ||
| Q2 25 | $150.0M | $132.5M | ||
| Q1 25 | $121.5M | $135.7M | ||
| Q4 24 | $118.8M | $145.8M | ||
| Q3 24 | $104.8M | $122.3M | ||
| Q2 24 | $87.2M | $130.8M | ||
| Q1 24 | $75.0M | $136.8M |
净利润AXSMRGR
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $1.6M | ||
| Q2 25 | $-48.0M | $-17.2M | ||
| Q1 25 | $-59.4M | $7.8M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $4.7M | ||
| Q2 24 | $-79.3M | $8.3M | ||
| Q1 24 | $-68.4M | $7.1M |
毛利率AXSMRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率AXSMRGR
| Q4 25 | -13.8% | 2.3% | ||
| Q3 25 | -27.0% | -2.7% | ||
| Q2 25 | -24.5% | -15.6% | ||
| Q1 25 | -46.9% | 6.2% | ||
| Q4 24 | -61.1% | 7.8% | ||
| Q3 24 | -59.8% | 3.1% | ||
| Q2 24 | -89.5% | 6.9% | ||
| Q1 24 | -89.7% | 5.5% |
净利率AXSMRGR
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 1.2% | ||
| Q2 25 | -32.0% | -13.0% | ||
| Q1 25 | -48.9% | 5.7% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 3.9% | ||
| Q2 24 | -91.0% | 6.3% | ||
| Q1 24 | -91.1% | 5.2% |
每股收益（稀释后）AXSMRGR
| Q4 25 | $-0.55 | $0.22 | ||
| Q3 25 | $-0.94 | $0.10 | ||
| Q2 25 | $-0.97 | $-1.05 | ||
| Q1 25 | $-1.22 | $0.46 | ||
| Q4 24 | $-1.54 | $0.62 | ||
| Q3 24 | $-1.34 | $0.28 | ||
| Q2 24 | $-1.67 | $0.47 | ||
| Q1 24 | $-1.44 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $322.9M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $88.3M | $283.8M |
| 总资产 | $689.8M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMRGR
| Q4 25 | $322.9M | $92.5M | ||
| Q3 25 | $325.3M | $80.8M | ||
| Q2 25 | $303.0M | $101.4M | ||
| Q1 25 | $300.9M | $108.3M | ||
| Q4 24 | $315.4M | $105.5M | ||
| Q3 24 | $327.3M | $96.0M | ||
| Q2 24 | $315.7M | $105.6M | ||
| Q1 24 | $331.4M | $115.3M |
股东权益AXSMRGR
| Q4 25 | $88.3M | $283.8M | ||
| Q3 25 | $73.7M | $279.6M | ||
| Q2 25 | $73.1M | $289.3M | ||
| Q1 25 | $53.2M | $321.5M | ||
| Q4 24 | $57.0M | $319.6M | ||
| Q3 24 | $92.9M | $314.9M | ||
| Q2 24 | $102.9M | $321.5M | ||
| Q1 24 | $144.0M | $332.0M |
总资产AXSMRGR
| Q4 25 | $689.8M | $342.0M | ||
| Q3 25 | $669.3M | $342.3M | ||
| Q2 25 | $639.8M | $349.5M | ||
| Q1 25 | $596.7M | $379.0M | ||
| Q4 24 | $568.5M | $384.0M | ||
| Q3 24 | $561.5M | $373.5M | ||
| Q2 24 | $548.2M | $376.7M | ||
| Q1 24 | $545.7M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-18.7M | $12.3M |
| 自由现金流率自由现金流/营收 | -9.6% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-93.9M | $38.5M |
8季度趋势，按日历期对齐
经营现金流AXSMRGR
| Q4 25 | $-18.7M | $15.5M | ||
| Q3 25 | $1.0M | $12.9M | ||
| Q2 25 | $-32.4M | $14.7M | ||
| Q1 25 | $-43.4M | $11.1M | ||
| Q4 24 | $-26.2M | $20.0M | ||
| Q3 24 | $-18.6M | $9.4M | ||
| Q2 24 | $-30.1M | $18.7M | ||
| Q1 24 | $-53.5M | $7.3M |
自由现金流AXSMRGR
| Q4 25 | $-18.7M | $12.3M | ||
| Q3 25 | $988.0K | $7.0M | ||
| Q2 25 | $-32.4M | $9.1M | ||
| Q1 25 | $-43.7M | $10.0M | ||
| Q4 24 | $-26.2M | $16.4M | ||
| Q3 24 | $-18.7M | $2.6M | ||
| Q2 24 | $-30.2M | $10.1M | ||
| Q1 24 | $-53.6M | $5.6M |
自由现金流率AXSMRGR
| Q4 25 | -9.6% | 8.2% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | -21.6% | 6.9% | ||
| Q1 25 | -36.0% | 7.4% | ||
| Q4 24 | -22.1% | 11.2% | ||
| Q3 24 | -17.9% | 2.1% | ||
| Q2 24 | -34.6% | 7.7% | ||
| Q1 24 | -71.4% | 4.1% |
资本支出强度AXSMRGR
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 5.5% | ||
| Q2 24 | 0.1% | 6.6% | ||
| Q1 24 | 0.1% | 1.3% |
现金转化率AXSMRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
